Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: Formulation and gender differences

Pharmacotherapy

Volumn 18, Issue 2 I, 1998, Pages 288-294

  Jann, Michael W ^a   ZumBrunnen, Troy L ^a   Tenjarla, Srini N ^a   Ward Jr , Earl S ^a   Weidler, Donald J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ONDANSETRON;

ADULT; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG FORMULATION; FEMALE; GENDER; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATION; RECTAL DRUG ADMINISTRATION; VOMITING;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; HEADACHE; HUMANS; MALE; ONDANSETRON; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; SEROTONIN ANTAGONISTS; SEX FACTORS; SUPPOSITORIES; TABLETS; TIME FACTORS;

EID: 0031896257     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Wilde MI, Markham A. Ondansetron. Drugs 1996;52:773-94.
2. Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995;29:95-109.
3. Simpson KH, Hicks FM. Clinical pharmacokinetics of ondansetron. A review. J Pharm Pharmacol 1996;48:774-81.
4. Bozigian CP, Pritchard JF, Gooding AE, Pakes GE. Ondansetron absorption in adults: effect of dosage form, food, and antacids. J Pharm Sci 1994;83:1011-13.
5. Hsyu PH, Pritchard JF, Bozigian HP, et al. Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon and to the rectum. Pharm Res 1994;11:156-9.
6. deWit R, Beijnen JH, van Telllngen O, Schllens JHM, BoerDennert M, Verweij J. Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. Br J Cancer 1996;74:323-6.
7. Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, Powell JR. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther 1992;51:51-5.
8. Fox JL, Ward ES, Tenjarla S. Formulation, dissolution, and efficacy of an extemporaneously prepared Zofran suppository dosage formulation. Presented at the 142nd annual meeting and exposition of the American Pharmaceutical Association, Orlando, FL, March 18-22, 1995.
9. Anonymous. Ondansetron suppositories. Int J Pharmaceut Compound 1997;1:34-5.
10. Colthup PV, Felgate CC, Palmer JL, Scully NJ. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. J Pharm Sci 1991;80:868-71.
11. Glaxo Wellcome. Ondansetron package insert. Research Triangle Park, NC; 1995.
12. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-39.
13. Dixon CM, Colthup PV, Serabjit-Singh CJ, et al. Multiple forms of cytochrome P 450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995;23:1225-30.
14. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP 1A2 activities. Clin Pharmacol Ther 1992;52:643-58.
15. Fuhr U, Rost KL. Simple and reliable CYP 1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva. Pharmacogenetics 1994;4:109-16.